Monday, October 18, 2021

Covid Treatments Big Business

US Set to Pay $712 Per Patient for Merck’s COVID-19 Pill

"Merck is set to get $712 per treatment course for its COVID-19 pill from the U.S. government—even as it costs a fraction of that to produce, and is reportedly on track for a price of $12 in India.

Public Citizen, an advocacy group, has urged the Biden administration to use executive authority to impose “a reasonable pricing requirement” so that “taxpayers don’t pay twice for medicine developed with public funds—first funding research and development, and again through excessive prices.”

Read about it...

No comments: